Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second‐line chemotherapy in patients with small cell lung cancer

Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second‐line chemotherapy in patients with small cell lung cancer

Abstract Background Amrubicin (AMR) regimens have shown efficacy as second‐line treatment in patients with small cell lung cancer (SCLC); however, adverse events such as febrile neutropenia (FN) sometimes preclude their use. Further, the safety and efficacy of AMR with primary prophylactic pegfilgra...

Full description

Bibliographic Details
Main Authors: Motoki Sekikawa, Haruyasu Murakami, Meiko Morita, Kosei Doshita, Keita Miura, Hiroaki Kodama, Noboru Morikawa, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Hirofumi Chiba, Toshiaki Takahashi
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:Thoracic Cancer
Subjects:
amrubicin
febrile neutropenia
pegfilgrastim
second‐line chemotherapy
small cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.15140

Internet

https://doi.org/10.1111/1759-7714.15140

Similar Items